A New Radiation Therapy Planning System in Patients Undergoing Radiation Therapy for Cancer
RATIONALE: A new radiation therapy planning system may help doctors plan better treatment for patients with cancer.
PURPOSE: This clinical trial is studying a new radiation therapy planning system in patients undergoing radiation therapy for extracranial cancer.
Unspecified Adult Solid Tumor, Protocol Specific
Radiation: radiation therapy
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Evaluation of the Radionics Body Localizer System and XPLAN/IMRT for Extra-Cranial Sites: A Pilot Study|
|Study Start Date:||June 2002|
|Study Completion Date:||August 2005|
- Determine the ability of the Radionics Body System™ to immobilize and re-localize patients receiving radiotherapy to extra-cranial sites of cancer.
- Determine the accuracy of radiation dose calculations for extra-cranial sites of cancer when using the XPLAN™-intensity modulated radiation therapy (XPLAN™/IMRT) integrated software in this system.
OUTLINE: Patients receiving radiotherapy have a Body Localizer cast constructed and undergo a CT scan while immobilized in the Body Localizer. Patients undergo another CT scan in the treatment position using the standard alpha cradle. The XPLAN™-intensity modulated radiation therapy (XPLAN™/IMRT)-generated treatment plan is compared to the standard treatment plan to verify that the calculated dose is within 2-3 percent of the planned dose using standard technique. Patients undergo sets of CT scans 3 additional times over the next few weeks for a total of 8 CT scans Patients may undergo additional CT scans before and after radiotherapy treatments for a maximum of 5 CT scans per week performed over the course of radiotherapy.
PROJECTED ACCRUAL: Approximately 60 patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00436397
|United States, Pennsylvania|
|Fox Chase Cancer Center - Philadelphia|
|Philadelphia, Pennsylvania, United States, 19111-2497|
|Study Chair:||Steven Seigenberg, MD||Fox Chase Cancer Center|